J Am Coll Cardiol 2016;68:1169–78.
The following adjustments were made to fit the CCI to the data available from the ENGAGE-AF TIMI 48 database: a Rankin score 3 to 5 was used instead of "hemiplegia"; rheumatoid arthritis was used for "rheumatic disease"; and patients with severe renal and severe hepatic disease, and patients with active cancer were excluded from ENGAGE AF–TIMI 48.
The following adjustments were made to fit the CCI to the data available from the ENGAGE-AF TIMI 48 database: a Rankin score 4 to 6 was used instead of "hemiplegia"; rheumatoid arthritis was used for "rheumatic disease"; and patients with severe renal and severe hepatic disease, and patients with active cancer were excluded from ENGAGE AF–TIMI 48.
Second sentence in table legend should have read: *In ENGAGE AF–TIMI 48, the dose of edoxaban was halved in patients with body weight ≤60 kg, a calculated creatinine clearance of 30 to 50 ml/min using the Cockcroft-Gault equation, or who required concomitant use of verapamil, quinidine, or dronedarone.
Adjusted HRs (adj HRs) and 95% CI comparing the relative efficacy and safety of edoxaban versus warfarin were calculated with the addition of adjustment for differences in baseline characteristics across randomized treatment groups in patients at increased risk of falling (Table 2: diastolic blood pressure, diabetes, and weight).
Adjusted HRs (adj HRs) and 95% CI comparing the relative efficacy and safety of edoxaban versus warfarin were calculated with the addition of adjustment for differences in baseline characteristics across randomized treatment groups in patients at increased risk of falling (Online Table 1: diastolic blood pressure, diabetes, and weight).
Patient characteristics were similar among the 3 treatment groups, except for lower diastolic pressure and higher prevalence of patients with weight <50 kg in the warfarin arm, and higher prevalence of diabetes in the HDER arm.
Patient characteristics were similar among the 3 treatment groups, except for lower diastolic pressure and higher prevalence of patients with weight ≤50 kg in the warfarin arm, and higher prevalence of diabetes in the HDER arm.
Central Illustration: The orange bar under Life-threatening bleeding should have read −141, NNT=71 and the blue bar should have read: −33, NNT=302. The revised Central illustration is printed below.
EP = endpoint; ICH = intracranial hemorrhage; life-threatening bleeding = ICH or bleeding associated with hemodynamic compromise requiring intervention; NNT = number needed to treat; SEE = systemic embolic event; 1° net clinical EP = death/stroke/SEE/major bleed; 2° net EP 2 = death or disabling stroke or life-threatening bleed; 3° net EP = death or stroke or SEE or life-threatening bleed.